(1) DJ EQS-News: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment EQS-News / 29/04/2021 / 11:36 UTC+8 Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO(R)), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinex
China to launch Heavenly Harmony space station core module
April 28, 2021
FacebookTwitterEmail
In this photo released by Xinhua News Agency, the core module of China s space station, Tianhe, on the the Long March-5B Y2 rocket is moved to the launching area of the Wenchang Spacecraft Launch Site in southern China s Hainan Province on April 23, 2021. China plans to launch the core module for its first permanent space station this week in the latest big step forward for the country’s space exploration program. The Tianhe, or “Heavenly Harmony” module is set to be hurtled into space aboard a Long March 5B rocket from the Wenchang Launch Center on the southern island of Hainan. The launch could come as early as Thursday night, April 29, 2021 if all goes as planned. (Guo Wenbin/Xinhua via AP)Guo Wenbin/AP
Stationery Giant M&G was designated as official partner of BFA 2021 yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
On a consolidated basis, ICICI Prudential Life Insurance Company net profit tanked 65% to Rs 62.51 crore on 364.6% surge in total income to Rs 19,898.29 crore in Q4 FY21 over Q4 FY20.
On a standalone basis, the net profit tumbled 64.5% to Rs 63.78 crore on 364.5% surge in total income to Rs 19,897.44 crore in Q4 FY21 over Q4 FY20. The company s net premium income increased by 13.40% to Rs 11,879.28 crore in Q4 FY21 over Rs 10,475.12 crore in Q3 FY20.
New business Annualised Premium Equivalent (APE) grew 27% Y-o-Y (year-on-year) in Q4 FY2021 to Rs 2,509 crore, on the back of 108% Y-o-Y growth in March 2021 to Rs 1,101 crore.
New business sum assured jumped 22.1% Y-o-Y to Rs 2,05,184 crore in Q4 FY2021 along with an expansion in new business premium by 22.9% to Rs 5,133 crore in the same period. The company was able to strengthen its position as the private sector market leader in terms of new business sum assured, with a market share of 13% in 11M FY2021, rising 11.8% from FY2020.